Relenza Prophylaxis Indication Withdrawn In EU; Pediatric Use Cleared In U.S.
Executive Summary
Glaxo Wellcome's influenza medication Relenza for prevention of flu was withdrawn from the EU mutual recognition process so the company could resubmit the application with more data in elderly and high-risk patients, Glaxo said.
You may also be interested in...
Relenza Growth Will Rely On Prophylaxis Use; Flovent Flies In U.S., Up 55%
A Relenza prophylaxis indication is key to the future growth of the inhaled neuraminidase inhibitor, Glaxo Wellcome Chairman Richard Sykes said July 27 at a half-year results meeting in London.
Relenza Growth Will Rely On Prophylaxis Use; Flovent Flies In U.S., Up 55%
A Relenza prophylaxis indication is key to the future growth of the inhaled neuraminidase inhibitor, Glaxo Wellcome Chairman Richard Sykes said July 27 at a half-year results meeting in London.
Roche Proteomics Group Focusing On Ways To Diagnosis Alzheimer's Disease
Measuring protein differences for the diagnosis and treatment of Alzheimer's disease is among the projects currently being pursued by Roche's proteomics group.